{"id":"W3026733513","doi":"10.1016/j.jval.2020.04.1588","title":"PCN87 COST-EFFECTIVENESS OF RIBOCILIB PLUS NONSTEROIDAL AROMATASE INHIBITOR (NSAI) IN HORMONE RECEPTOR–POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–NEGATIVE (HR+/HER2-) ADVANCED BREAST CANCER (ABC): A CANADIAN HEALTHCARE PERSPECTIVE","year":2020,"lang":"en","type":"article","venue":"Value in Health","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Medicine; Discontinuation; Breast cancer; Internal medicine; Quality-adjusted life year; Population; Placebo; Oncology; Exemestane; Adverse effect; Hazard ratio; Cohort; Cancer; Cost effectiveness; Confidence interval; Pathology; Aromatase; Environmental health","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001218471,0.0005816153,0.001228663,0.0007638104,0.0004667048,0.001840754,0.0008711975,0.0009537797,0.006570285],"category_scores_gemma":[0.003272458,0.0002584944,0.002197875,0.001484682,0.0005917755,0.0004691594,0.000417845,0.001607747,0.0003226394],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.03939098,"about_ca_system_score_gemma":0.03408571,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.7374967,"about_ca_topic_score_gemma":0.8847314,"domain_scores_codex":[0.9986626,0.0004120078,0.00006770893,0.00008624358,0.0004473974,0.0003239751],"domain_scores_gemma":[0.9987547,0.0002824769,0.0001919545,0.00001801243,0.000297698,0.0004552336],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.0900519,0.002061428,0.04107605,0.00558997,0.00807228,0.0008992415,0.0003402279,0.0444148,0.00346018,0.01496254,0.0746615,0.7144099],"study_design_scores_gemma":[0.05442487,0.03892226,0.5650091,0.01120116,0.03945384,0.002505814,0.002872316,0.05755749,0.003473984,0.01009075,0.2138498,0.000638677],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.5805543,0.2468501,0.001255593,0.05500939,0.001341023,0.0008373269,0.01440483,0.0001447594,0.09960262],"genre_scores_gemma":[0.9538441,0.03485471,0.001355057,0.002784408,0.0004632552,0.00007344317,0.002761423,0.00001780237,0.003845801],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2625033,"threshold_uncertainty_score":0.5280983,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03851986799938985,"score_gpt":0.3323232837129566,"score_spread":0.2938034157135667,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}